MedTrace Logo

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

NCT06826768 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-08

No results posted yet for this study

Summary

A single-center phase Ib/II dose escalation and dose-expansion clinical trial of REGN5678 plus cemiplimab

Conditions

Interventions

DRUG

REGN5678

Given by IV infusion

DRUG

Cemiplimab

Given by IV infusion

Sponsors & Collaborators

Principal Investigators

  • Bilal Siddiqui, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-09
Primary Completion
2027-05-01
Completion
2029-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06826768 on ClinicalTrials.gov